Hoffmann-la Roche Inc.

Kinarus Ag

F. Hoffmann-la Roche Ag

Matthew Wright

Bernd Kuhn

Henrietta Dehmlow

Narendra Panday

Hasane Ratni

Uwe Grether

Stephan Roever

Peter Mohr

Johannes Aebi

Jean Ackermann

Alfred Binggeli

Georges Hirth

Tanja Schulz-Gasch

Hans-Peter Maerki

Markus Meyer

Raffaello Masciadri

Paul Hebeisen

Ulrike Obst Sander

Hugues Matile

Constantinos G Panousis

Hans G Richter

Rainer Eugen Martin

Konrad H Bleicher

Rene Wyler

Minmin Yang

Alexander Chucholowski

Eric Joseph Niesor

Pius Waldmeier

Gregory Martin Benson

Franz Schuler

Sannah Zoffmann Jensen

Alexander Bausch

Xavier Marie Warot

Sannah Zoffman Jensen

René Wyler

The present invention relates to a pharmaceutical combination comprising:

Methods of preventing or treating ophthalmic diseases

The present invention relates to compounds of the formula wherein A, A, Aand Rto Rare defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

Heteroarylmethyl amides

The invention is concerned with novel piperazine amide derivatives of formula (I) wherein Rto R, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Piperazine amide derivatives

The present invention relates to a compound of formula I, in all its isomeric forms and pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.

[object Object]

The present invention relates to pyrazine derivatives of the formula and pharmaceutically acceptable salts thereof, wherein Rto Rare as defined in the description and claims for use as HDL-cholesterol raising agents in the treatment and/or prophylaxis of diseases or disorders that can be treated with such agents such as dyslipidemia.

3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents

The invention is concerned with novel imidazolidine derivatives of formula (I) wherein Rto R, A, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Imidazolidine derivatives

The invention is concerned with novel biaryl sulfonamide derivatives of formula (I) wherein Rto Rand Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Biaryl sulfonamide derivatives

The present invention relates to compounds of the formula (I) wherein R, R, R, R, R, X, X, X, X, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXR&#x3b1; and/or LXR&#x3b2; agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

Tetrahydrocarbazoles and derivatives

The present invention relates to compounds formula I: and pharmaceutically acceptable salts thereof, wherein Rto Rare as defined in the description and claims for use as HDL-cholesterol raising agents in the treatment and/or prophylaxis of diseases or disorders that can be treated with such agents such as dyslipidemia.

2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents

The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I) wherein Rto R, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Hexafluoroisopropanol derivatives

The invention is concerned with novel benzimidazole derivatives of formula (I) wherein Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to Farnesoid-X-receptors (FXR) and can be used to treat diseases which are modulated by FXR agonists such as diabetes and dyslipidemia.

Benzimidazole derivatives

The invention is concerned with novel imidazolidinone derivatives of formula (I): wherein Rto Rand X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used in pharmaceutical compositions.

Imidazolidinone derivatives

There are presented compounds of the formula  Rand Ror Rand Rtogether with the carbon atoms to which they are attached, form a ring as defined in the description and X, X, Yto Y, Rto Rand n are as specified in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR&#x3b4; and/or PPAR&#x3b1; agonists.

Growing community of inventors

Basel, Switzerland

Matthew Wright